← All Dyne Therapeutics, INC filings

Dyne Therapeutics, INC 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

NASDAQ
DYN
Dyne Therapeutics, INC
10-Q: Dyne Therapeutics Q1 2026 Earnings: Increased R&D, Net Loss Widens
Dyne Therapeutics reported a wider net loss for Q1 2026, driven by increased research and development expenses, particularly for its z-rostudirsen program, while general and administrative costs also rose.
NASDAQ
DYN
Dyne Therapeutics, INC
10-Q: Dyne Therapeutics Advances DM1, DMD Programs; Secures Funding
Dyne Therapeutics reports positive clinical data for its lead programs, z-basivarsen and z-rostudirsen, while securing significant financing to extend its cash runway into Q3 2027.
NASDAQ
DYN
Dyne Therapeutics, INC
10-Q: Dyne Therapeutics Reports Strong Clinical Progress for DM1 and DMD Programs, Secures Substantial Funding to Extend Runway
Dyne Therapeutics announced positive long-term efficacy and safety data for its lead programs, DYNE-101 for DM1 and DYNE-251 for DMD, alongside securing significant financing that extends its cash runway into the third quarter of 2027.
NASDAQ
DYN
Dyne Therapeutics, INC
10-Q: Dyne Therapeutics Announces Executive Separation and Q1 2025 Results, Highlighting Clinical Trial Progress
Dyne Therapeutics reports the separation of an executive, Q1 2025 financial results, and provides updates on its ongoing clinical trials for DYNE-101 and DYNE-251.
NASDAQ
DYN
Dyne Therapeutics, INC
10-Q: Dyne Therapeutics Reports Strong Cash Position and Clinical Trial Progress in Q3 2024
Dyne Therapeutics' Q3 2024 filing highlights a robust cash position of $723.7 million and positive clinical trial data for its lead programs.
NASDAQ
DYN
Dyne Therapeutics, INC
10-Q: Dyne Therapeutics Reports Strong Cash Position and Positive Clinical Trial Data in Q2 2024
Dyne Therapeutics' Q2 2024 filing reveals a robust cash position and encouraging clinical trial results for its lead programs.
NASDAQ
DYN
Dyne Therapeutics, INC
10-Q: Dyne Therapeutics Reports First Quarter 2024 Results, Bolstered by Successful Capital Raise
Dyne Therapeutics' first quarter 2024 results show a significant increase in cash and marketable securities following a substantial capital raise, alongside ongoing clinical trial advancements.